MedTrace Logo

Safety and Tolerability of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars

NCT06210919 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2025-08-12

No results posted yet for this study

Summary

The purpose of this clinical trial was to evaluate the safety and tolerability for 12 weeks after one dose of TRTP-101 in adults with atrophic scars.

Conditions

  • Atrophic Scar

Interventions

BIOLOGICAL

TRTP-101

Intradermal injection of the each of four sites

Sponsors & Collaborators

  • CellinCells

    lead INDUSTRY

Principal Investigators

  • Jonghee Lee, MD · Samsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-06
Primary Completion
2024-12-10
Completion
2025-03-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06210919 on ClinicalTrials.gov